DE69841395D1 - Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie - Google Patents
Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von HyperlipidämieInfo
- Publication number
- DE69841395D1 DE69841395D1 DE69841395T DE69841395T DE69841395D1 DE 69841395 D1 DE69841395 D1 DE 69841395D1 DE 69841395 T DE69841395 T DE 69841395T DE 69841395 T DE69841395 T DE 69841395T DE 69841395 D1 DE69841395 D1 DE 69841395D1
- Authority
- DE
- Germany
- Prior art keywords
- nicotinic acid
- nicotinamide
- methyl
- composition
- hmg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 7
- 239000011664 nicotinic acid Substances 0.000 title abstract 5
- 229960003512 nicotinic acid Drugs 0.000 title abstract 5
- 235000001968 nicotinic acid Nutrition 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- -1 nicotinic acid compound Chemical class 0.000 title abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- IMRLNFKFNFLWQF-IYKITFJXSA-N sorbinicate Chemical compound O([C@H](COC(=O)C=1C=NC=CC=1)[C@@H](OC(=O)C=1C=NC=CC=1)[C@H](OC(=O)C=1C=NC=CC=1)[C@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 IMRLNFKFNFLWQF-IYKITFJXSA-N 0.000 abstract 2
- 206010072268 Drug-induced liver injury Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
- KTLRWTOPTKGYQY-UHFFFAOYSA-N N-methyl-4-pyridone-3-carboxamide Chemical compound CN1C=CC(=O)C(C(N)=O)=C1 KTLRWTOPTKGYQY-UHFFFAOYSA-N 0.000 abstract 1
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 abstract 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 abstract 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 abstract 1
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940056243 aluminium nicotinate Drugs 0.000 abstract 1
- NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960000827 niceritrol Drugs 0.000 abstract 1
- NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 abstract 1
- 229960000839 nicotinyl alcohol tartrate Drugs 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229950007581 sorbinicate Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90375297A | 1997-07-31 | 1997-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69841395D1 true DE69841395D1 (de) | 2010-01-28 |
Family
ID=25418027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837610T Expired - Lifetime DE69837610T2 (de) | 1997-07-31 | 1998-07-31 | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung |
| DE69841395T Expired - Lifetime DE69841395D1 (de) | 1997-07-31 | 1998-07-31 | Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837610T Expired - Lifetime DE69837610T2 (de) | 1997-07-31 | 1998-07-31 | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20040053975A1 (de) |
| EP (2) | EP1017390B1 (de) |
| JP (2) | JP4870869B2 (de) |
| AT (2) | ATE451926T1 (de) |
| AU (1) | AU752673B2 (de) |
| BR (1) | BR9815548A (de) |
| CA (1) | CA2298549C (de) |
| CY (1) | CY1107057T1 (de) |
| DE (2) | DE69837610T2 (de) |
| DK (1) | DK1017390T3 (de) |
| ES (2) | ES2336492T3 (de) |
| IL (2) | IL134271A0 (de) |
| NO (1) | NO20000439L (de) |
| NZ (1) | NZ520176A (de) |
| PT (1) | PT1017390E (de) |
| WO (1) | WO1999006035A2 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE970731A1 (en) † | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
| DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| HK1046092A1 (zh) * | 1999-07-14 | 2002-12-27 | Genzyme Corporation | 可與脂解酶抑制劑任意配合的脂肪結合聚合物 |
| JP2001131151A (ja) * | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| CZ20024015A3 (cs) † | 2000-06-09 | 2003-04-16 | Lek Pharmaceutical D.D. | Stabilní farmaceutický produkt a jeho formulace |
| US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
| AU2001295991A1 (en) * | 2000-10-23 | 2002-05-06 | Sankyo Company Limited | Compositions for improving lipids in blood |
| WO2002038151A1 (fr) * | 2000-11-07 | 2002-05-16 | Sankyo Company, Limited | Compositions permettant de reduire la concentration de peroxydes lipidiques |
| TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1413331B1 (de) | 2001-01-26 | 2007-10-03 | Schering Corporation | Kombinationen vom PPAR-Aktivator Fenofibrat mit dem Hemmer der Sterol-Absorption Ezetimibe zur Behandlung von kardiovaskulären Indikationen |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| MY138301A (en) | 2001-01-26 | 2009-05-29 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2002336609B2 (en) | 2001-09-21 | 2006-08-24 | Merck Sharp & Dohme Corp. | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
| CN100415235C (zh) * | 2002-08-02 | 2008-09-03 | 三共株式会社 | 含有HMG-CoA还原酶抑制剂的药物组合物 |
| TW200409635A (en) * | 2002-08-02 | 2004-06-16 | Sankyo Co | A pharmaceutical composition containing a HMG-CoA reductase |
| JP4607436B2 (ja) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物 |
| JP2006508188A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| MXPA05009502A (es) | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| WO2004081003A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| KR20060033033A (ko) * | 2003-08-04 | 2006-04-18 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형 |
| US20050148556A1 (en) * | 2003-10-29 | 2005-07-07 | Raif Tawakol | Compositions and methods for increasing HDL and HDL-2b levels |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| DK1919466T3 (da) * | 2005-07-11 | 2012-07-02 | Cortria Corp | Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat |
| KR20070063350A (ko) * | 2005-12-14 | 2007-06-19 | 주식회사종근당 | 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물 |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| JP5628480B2 (ja) * | 2006-03-09 | 2014-11-19 | グラクソスミスクライン エルエルシー | 医薬成分を含有するコーティングカプセル |
| WO2008023958A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
| KR100885029B1 (ko) * | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
| WO2009016577A2 (en) * | 2007-07-27 | 2009-02-05 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising atorvastatin and niacin |
| KR20090091075A (ko) * | 2008-02-22 | 2009-08-26 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
| KR101164300B1 (ko) * | 2008-02-22 | 2012-07-09 | 한올바이오파마주식회사 | 약제학적 제제 |
| JP2011512406A (ja) * | 2008-02-22 | 2011-04-21 | ハナル バイオファーマ カンパニー リミテッド | 複合製剤 |
| JP2011521915A (ja) * | 2008-05-20 | 2011-07-28 | セレニス セラピューティクス エス．エー． | ナイアシン及びｎｓａｉｄ併用療法 |
| WO2009149056A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Combinations of niacin and an oxicam |
| AU2009256394A1 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Modified release niacin formulations |
| US20100178341A1 (en) * | 2008-06-11 | 2010-07-15 | Ranbaxy Laboratories Limited | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR |
| EP2310004A1 (de) * | 2008-07-11 | 2011-04-20 | Kareus Therapeutics SA | Niacinzusammensetzungen für verminderte produktion von amyloid-beta-peptid 42 (abeta 42) und zur behandlung von morbus alzheimer |
| CN102458117B (zh) * | 2009-05-01 | 2015-11-25 | 阿普塔利斯医药科技公司 | 含有非阿片样和阿片样止痛药的组合的口腔崩解片组合物 |
| CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
| KR102065193B1 (ko) | 2011-05-20 | 2020-01-10 | 아스트라제네카 유케이 리미티드 | 로수바스타틴 칼슘의 약학 조성물 |
| CN111704543A (zh) | 2014-11-14 | 2020-09-25 | 燿石治疗公司 | 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体 |
| CA3001627A1 (en) * | 2015-11-06 | 2017-05-11 | Gemphire Therapeutics, Inc. | Treatment of mixed dyslipidemia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524001A (en) * | 1965-03-04 | 1970-08-11 | Upjohn Co | Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles |
| JPS63310827A (ja) * | 1987-06-15 | 1988-12-19 | Sanwa Kagaku Kenkyusho Co Ltd | ニコチン酸誘導体を主剤とする徐放性製剤 |
| US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| CA2018470A1 (en) * | 1989-07-17 | 1991-01-17 | Scott Adams Biller | Phosphorus-containing squalene synthetase inhibitors and method |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| US5840339A (en) * | 1991-07-30 | 1998-11-24 | Kunin; Robert | Blood cholesterol reducing pharmaceutical composition |
| EP0543417A1 (de) * | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienole und Focotrienol-ähnliche Verbindungen und Verfahren zu ihrer Verwendung |
| US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
| US6080428A (en) * | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
| US5773453A (en) * | 1995-04-19 | 1998-06-30 | Vanderbilt University | Methods for administration of antilipemic drugs |
| WO1996032942A1 (en) * | 1995-04-19 | 1996-10-24 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
-
1998
- 1998-07-31 DE DE69837610T patent/DE69837610T2/de not_active Expired - Lifetime
- 1998-07-31 DE DE69841395T patent/DE69841395D1/de not_active Expired - Lifetime
- 1998-07-31 IL IL13427198A patent/IL134271A0/xx active IP Right Grant
- 1998-07-31 DK DK98938228T patent/DK1017390T3/da active
- 1998-07-31 WO PCT/US1998/015990 patent/WO1999006035A2/en active IP Right Grant
- 1998-07-31 AU AU86801/98A patent/AU752673B2/en not_active Ceased
- 1998-07-31 NZ NZ520176A patent/NZ520176A/en not_active IP Right Cessation
- 1998-07-31 AT AT07003276T patent/ATE451926T1/de not_active IP Right Cessation
- 1998-07-31 EP EP98938228A patent/EP1017390B1/de not_active Expired - Lifetime
- 1998-07-31 ES ES07003276T patent/ES2336492T3/es not_active Expired - Lifetime
- 1998-07-31 PT PT98938228T patent/PT1017390E/pt unknown
- 1998-07-31 CA CA002298549A patent/CA2298549C/en not_active Expired - Lifetime
- 1998-07-31 JP JP2000504849A patent/JP4870869B2/ja not_active Expired - Fee Related
- 1998-07-31 BR BR9815548-2A patent/BR9815548A/pt not_active Application Discontinuation
- 1998-07-31 ES ES98938228T patent/ES2283067T3/es not_active Expired - Lifetime
- 1998-07-31 AT AT98938228T patent/ATE359785T1/de active
- 1998-07-31 EP EP07003276A patent/EP1792616B1/de not_active Expired - Lifetime
-
2000
- 2000-01-27 NO NO20000439A patent/NO20000439L/no not_active Application Discontinuation
- 2000-01-27 IL IL134271A patent/IL134271A/en not_active IP Right Cessation
-
2003
- 2003-09-02 US US10/260,027 patent/US20040053975A1/en not_active Abandoned
-
2007
- 2007-05-07 CY CY20071100604T patent/CY1107057T1/el unknown
-
2009
- 2009-02-27 US US12/394,441 patent/US20090226518A1/en not_active Abandoned
- 2009-07-22 JP JP2009170721A patent/JP2009235105A/ja active Pending
-
2011
- 2011-10-27 US US13/282,755 patent/US20120164221A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040053975A1 (en) | 2004-03-18 |
| PT1017390E (pt) | 2007-07-24 |
| NO20000439L (no) | 2000-03-22 |
| AU8680198A (en) | 1999-02-22 |
| ATE451926T1 (de) | 2010-01-15 |
| ES2283067T3 (es) | 2007-10-16 |
| HK1106153A1 (en) | 2008-03-07 |
| DE69837610D1 (de) | 2007-05-31 |
| WO1999006035A2 (en) | 1999-02-11 |
| CY1107057T1 (el) | 2012-10-24 |
| IL134271A (en) | 2006-07-05 |
| EP1017390B1 (de) | 2007-04-18 |
| US20120164221A1 (en) | 2012-06-28 |
| JP4870869B2 (ja) | 2012-02-08 |
| CA2298549A1 (en) | 1999-02-11 |
| NZ520176A (en) | 2005-02-25 |
| NO20000439D0 (no) | 2000-01-27 |
| US20090226518A1 (en) | 2009-09-10 |
| JP2009235105A (ja) | 2009-10-15 |
| JP2001511444A (ja) | 2001-08-14 |
| EP1017390A2 (de) | 2000-07-12 |
| AU752673B2 (en) | 2002-09-26 |
| EP1792616B1 (de) | 2009-12-16 |
| DK1017390T3 (da) | 2007-06-11 |
| WO1999006035A3 (en) | 1999-04-22 |
| IL134271A0 (en) | 2001-04-30 |
| DE69837610T2 (de) | 2008-01-03 |
| CA2298549C (en) | 2006-01-10 |
| EP1792616A1 (de) | 2007-06-06 |
| ES2336492T3 (es) | 2010-04-13 |
| ATE359785T1 (de) | 2007-05-15 |
| BR9815548A (pt) | 2000-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69841395D1 (de) | Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie | |
| NO973814D0 (no) | Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor | |
| CA2356158A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications | |
| AU652977B2 (en) | Substituted pyridyl-dihydroxy-heptenoic acid and its salts | |
| EP1004578A3 (de) | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate | |
| EP0773022A3 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| DE69600001D1 (de) | Kosmetische Zusammensetzung, die eine Silikonverbindung und einen Fettsäureester enthält | |
| IL99064A0 (en) | Substituted pyrroles,their preparation and pharmaceutical compositions containing them | |
| RS49504B (sr) | Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze | |
| KR970706807A (ko) | 메티오날 또는 말론디알데히드의 세포 내 비율에 영향을 미치는 성분을 함유하는 세포소멸(Capoptosis) 조절 조성물(APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE) | |
| GB9718903D0 (en) | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| DE69300062D1 (de) | Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon. | |
| DE59604829D1 (de) | Kontinuierliches Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethylpiperidin | |
| TW355709B (en) | Quinoline carboxylic acid derivative | |
| CA2385863A1 (en) | New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | |
| NO20053581L (no) | Optisk aktivt dihydropyridinderivat. | |
| CA2419588A1 (en) | Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors | |
| AU3011295A (en) | Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments | |
| AU3108393A (en) | Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use | |
| NO932874L (no) | Anvendelse av lacidipin for behandling av arteriosklerose | |
| NO960777D0 (no) | Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter | |
| DE59306506D1 (de) | 4-Heterocyclyl substituierte Dihydropyridine | |
| WO2001091535A3 (en) | A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält | |
| ATE248158T1 (de) | Synthese von optisch reinen verbindungen als garft-inhibitoren und deren zwischenprodukte | |
| AU4164693A (en) | Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |